Drugmakers Contend Inter Partes Review Ignores Statutes, Skews Outcomes

Drug Industry Daily
A A
The formal process for disputing a patent before the U.S. Patent and Trademark Office skirts statutory requirements and provides drugmakers with an unfair proceeding that skews outcomes, industry said.

To View This Article:

Login

Subscribe To Drug Industry Daily